- Mixed schedules involving Pfizer-BioNTech and Oxford-AstraZeneca generate strong immune response against SARS-CoV2 spike IgG protein
- Doses administered four weeks apart; data for 12-week dose interval due soon.
- Immune responses differed according to order of immunisation, with Oxford-AstraZeneca followed by Pfizer-BioNTech generating the better immune response out of the two mixed schedules.
In a paper published on the Lancet pre-print server, they report that both ‘mixed’ schedules (Pfizer-BioNTech followed by Oxford-AstraZeneca, and Oxford-AstraZeneca followed by Pfizer-BioNTech) induced high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered four weeks apart.
This means all possible vaccination schedules involving the Oxford-AstraZeneca and Pfizer-BioNTech vaccines could potentially be used against COVID-19.